Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iN1011-N17-02 in Post herpetic Neuralgia
2024-518747-38-00Phase 2Completed
- Sponsor
- iN Therapeutics
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing iN1011-N17-02 with Placebo (2 arms). Primary endpoint: Change in average weekly NRS pain score from Baseline to Week 4. Started Jul 2025; status: completed.
02
Drugs
iN1011-N17
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2024-518747-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518747-38-00.